Quinoxalinone-based, endoplasmic reticulum-targeting photosensitizer nanoparticles for tumor photodynamic therapy.

The endoplasmic reticulum (ER) is an indispensable organelle responsible for the synthesis and transport of proteins and membrane lipids, playing a critical role in numerous physiological and pathological processes. Leveraging the properties of the ER, we developed novel quinoxalinone-based, ER-targeting photosensitizer nanoparticles (Qui-PS NPs) by conjugating an ER-specific targeting peptide(RACR) and evaluated their photodynamic therapy (PDT) efficacy. The size, morphology, cellular uptake, ER targeting capability, cell viability, biodistribution, and antitumor efficacy were assessed using dynamic light scattering, transmission electron microscopy, confocal microscopy, CCK-8 assay, ICP-Mass spectrometry, and tumor volume measurements, respectively. The results demonstrated that the synthesized Qui-PS NPs possessed an average diameter of 79.74 ± 9.4 nm, a polydispersity index (PDI) of 0.23 ± 0.02 , and a Zeta potential of - 11.63 ± 2.86 mV. These nanoparticles exhibited near-infrared fluorescence emission centered at 830 nm and demonstrated superior singlet oxygen (1O2) generation capability. The NPs were readily internalized by MCF-7 cells, displayed specific ER targeting, and induced cytotoxic effects upon light irradiation, with an I C 50 value of 3.2 ± 0.06 μg/mL. In tumor-bearing mice, Qui-PS NPs preferentially accumulated in tumor tissue and significantly suppressed tumor progression under light irradiation, with minimal impact on body weight. These findings suggest that these ER-targeted NPs represent a promising nanoplatform for potential application in tumor PDT.